 |
|
Clinical Cancer Chemotherapy Aimed at Potential Cell Regulators
Frances E. Knock, PhD, MD;
Raymond M. Gait, MD;
Oliver V. Renaud, MD;
Y. Thomas Oester, MD, PhD
AMA Arch Surg. 1970;100(2):167-172.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Marked toxicity to wound healing and bone marrow has plagued clinical cancer chemotherapy, with drugs like mechlorethamine hydrochloride (nitrogen mustard) and fluorouracil (5-fluorouracil) attacking nucleic acids or blocking their synthesis. For adjuvant chemotherapy following cancer surgery, anticancer drugs must attack cancer preferentially, to permit normal wound healing while regressing cancer. The search for cancerocidal drugs that can be used immediately after major cancer surgery has led to clinical use of selected drugs attacking potential cellular regulators.1-3 These drugs have regressed a variety of human cancers without injury to wound healing and with minimal injury to hematologic status, or even improvement in some patients.
Cellular regulators are generally believed to be proteins. For attack at potential regulatory proteins of chromosomes, cytoplasm, cell membranes, and steroid receptors, sulfhydryl (SH) groups on protein appear to be the most reactive and vulnerable, and the most essential for maintaining proper architecture of the proteins
. . . [Full Text PDF of this Article]
Author Affiliations
Chicago; Hines, Ill
From the Nelson M. Percy Research Foundation, Augustana Hospital, and the University of Illinois College of Medicine, Chicago (Drs. Knock, Gait, and Renaud), the Veterans Administration Hospital, Hines, Ill (Drs. Knock and Oester), and Loyola University Stritch School of Medicine, Maywood, Ill (Dr. Oester).
Footnotes
Submitted for publication Feb 25, 1969.
Reprint requests to 411 W Dickens Ave, Chicago 60614 (Dr. Knock).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
